EUVIMEDEUVIMED entdecken
Crossref

Serious Infection in Inflammatory Bowel Diseases Patients Treated With Vedolizumab, Ustekinumab, Janus Kinase Inhibitors, Anti–Tumor Necrosis Factor or Aminosalicylates

Anaïs Bertrand, Aurélien Amiot, Antoine Martin, Franck Carbonnel, Antoine Meyer

Clinical Gastroenterology and Hepatology · 2026-11 · 24 (11) · 3124-3136

DOI: 10.1016/j.cgh.2026.04.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-11. Verfasst von Anaïs Bertrand und 4 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Antibodies, Monoclonal, Humanized, Ustekinumab, Aminosalicylic Acids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Advanced therapy including biologics and Janus kinase inhibitors are commonly used to treat inflammatory bowel diseases. We aimed to assess the risk of serious infection in patients with inflammatory bowel diseases treated with advanced therapies. METHODS: This was a nationwide French cohort including patients with inflammatory bowel diseases aged >15 years, initiating treatment between 2014 and 2024: vedolizumab, ustekinumab, Janus kinase inhibitors, anti-tumor necrosis factors, or aminosalicylates. We assessed serious infection according to treatment exposure. Propensity score weighting accounted for indication bias. RESULTS: A total of 309,025 treatments were initiated in 219,229 patients: 27,514 initiated vedolizumab, 28,054 ustekinumab, 6439 Janus kinase inhibitors, 93,444 anti-tumor necrosis factors, and 153,574 aminosalicylates. The median age was 41 years (interquartile range, 29-55 years), 52.0% were women, and 45.3% had Crohn's disease. A total of 15,081 serious infections occurred over a median follow-up of 1.0 years. Compared with aminosalicylates, the adjusted hazard ratios for serious infections were 1.05 (95% confidence interval, 0.98-1.11) for ustekinumab, 1.29 (95% confidence interval, 1.24-1.34) for anti-tumor necrosis factors, 1.38 (95% confidence interval, 1.30-1.46) for vedolizumab, and 1.63 (95% confidence interval, 1.45-1.84) for Janus kinase inhibitors. Compared with anti-tumor necrosis factors, the adjusted hazard ratios were 0.81 (95% confidence interval, 0.76-0.86) for ustekinumab, 1.07 (95% confidence interval, 1.01-1.13) for vedolizumab, and 1.27 (95% confidence interval, 1.12-1.43) for Janus kinase inhibitors. Patterns were consistent across inflammatory bowel disease type. Anti-tumor necrosis factors and vedolizumab were particularly associated with skin, upper respiratory tract, and central nervous system infections. Janus kinase inhibitors were particularly associated with herpesvirus infections, and anti-tumor necrosis factor with mycobacterial infections. Concomitant corticosteroids and thiopurine/methotrexate increased the risks of serious infection by 2.06 (95% confidence interval, 1.98-2.14) and 1.11 (95% confidence interval, 1.06-1.16), respectively. CONCLUSIONS: Among patients with inflammatory bowel diseases, the risk of serious infection is highest with Janus kinase inhibitors, lowest with ustekinumab, and intermediate with anti-tumor necrosis factors and vedolizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesAntibodies, Monoclonal, HumanizedUstekinumabAminosalicylic AcidsGastrointestinal AgentsJanus Kinase InhibitorsInfectionsHumansFemaleAdultMiddle AgedMaleFranceTumor Necrosis Factor-alphaCohort Studies

Stichwörter der Autor:innen

BiologicsInflammatory Bowel DiseaseJAK InhibitorSerious Infection

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedUstekinumabAminosalicylic AcidsGastrointestinal AgentsJanus Kinase InhibitorsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France.
  • Service de Gastroentérologie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Paris-Saclay, Le Kremlin Bicêtre, France; Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France. Electronic…

Zitieren

APA

Bertrand, A., Amiot, A., Martin, A., Carbonnel, F., & Meyer, A. (2026). Serious Infection in Inflammatory Bowel Diseases Patients Treated With Vedolizumab, Ustekinumab, Janus Kinase Inhibitors, Anti–Tumor Necrosis Factor or Aminosalicylates. Clinical Gastroenterology and Hepatology, 24(11), 3124-3136. https://doi.org/10.1016/j.cgh.2026.04.015

Vancouver

Bertrand A, Amiot A, Martin A, Carbonnel F, Meyer A. Serious Infection in Inflammatory Bowel Diseases Patients Treated With Vedolizumab, Ustekinumab, Janus Kinase Inhibitors, Anti–Tumor Necrosis Factor or Aminosalicylates. Clinical Gastroenterology and Hepatology. 2026;24(11):3124-3136. doi:10.1016/j.cgh.2026.04.015

BibTeX
@article{Bertrand2026,
  author = {Bertrand, Anaïs and Amiot, Aurélien and Martin, Antoine and Carbonnel, Franck and Meyer, Antoine},
  title = {Serious Infection in Inflammatory Bowel Diseases Patients Treated With Vedolizumab, Ustekinumab, Janus Kinase Inhibitors, Anti–Tumor Necrosis Factor or Aminosalicylates},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {11},
  pages = {3124--3136},
  doi = {10.1016/j.cgh.2026.04.015}
}
Kostenlos starten →